The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Cannabinoids in the management of difficult to treat pain
Open accessAbstract
This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment. Tetrahydrocannabinol (THC, Marinol((R))) and nabilone (Cesamet((R))) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex((R)), a cannabis derived oromucosal spray containing equal proportions of THC (partial CB(1) receptor agonist ) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB(1) receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Coxibs and Cardiovascular Disease
FitzGerald, G. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048288 · Cited by 899
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment
Solowij, N. (2002) · JAMA · doi:10.1001/jama.287.9.1123 · Cited by 798
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Neuropsychological Performance in Long-term Cannabis Users
Pope, H. G., Gruber, A. J., Hudson, J. I., Huestis, M. A., & Yurgelun-Todd, D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.909 · Cited by 655
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Self-citationShen, M., Piser, T. M., Seybold, V. S., & Thayer, S. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04322.1996 · Cited by 604
Failing the Public Health — Rofecoxib, Merck, and the FDA
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048286 · Cited by 599
Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253187.66183.9c · Cited by 598
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors
Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C. E., Brenner, G. J., Rubino, T., Michalski, C. W., Marsicano, G., Monory, K., et al. (2007) · Nature Neuroscience · doi:10.1038/nn1916 · Cited by 571
Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., & Di Marzo, V. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105247 · Cited by 568
Review of the Validity and Significance of Cannabis Withdrawal Syndrome
Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1967 · Cited by 522
Huestis, M. A., Henningfield, J. E., & Cone, E. J. (1992) · Journal of Analytical Toxicology · doi:10.1093/jat/16.5.276 · Cited by 519
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
Richardson, J. D., Kilo, S., & Hargreaves, K. M. (1998) · Pain · doi:10.1016/s0304-3959(97)00213-3 · Cited by 500
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497
Pain modulation by release of the endogenous cannabinoid anandamide
Walker, J. M., Huang, S. M., Strangman, N. M., Tsou, K., & Sañudo-Peña, M. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12198 · Cited by 485
Wade, D. T., Robson, P., House, H., Makela, P., & Aram, J. (2003) · Clinical Rehabilitation · doi:10.1191/0269215503cr581oa · Cited by 441
Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006) · Rheumatology · doi:10.1093/rheumatology/kei183 · Cited by 433
Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007) · Pain · doi:10.1016/j.pain.2007.08.028 · Cited by 431 · cited 3×
“In a Phase III double-blind, placebo-controlled trial (N = 125) of peripheral neuropathic pain with allodynia (Nurmikko et al 2007), Sativex produced highly statistically signifi cant improvements in pain levels, dynamic and punctate allodynia (Table 1).”
BackgroundResultCampbell, F. A., Tramèr, M. R., Carroll, D., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.13 · Cited by 423
Marijuana and medicine: assessing the science base
(1999) · Choice Reviews Online · doi:10.5860/choice.37-2206 · Cited by 410
Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., & James, I. (2001) · Pain · doi:10.1016/s0304-3959(00)00474-7 · Cited by 379
Berman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362
Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003) · JAMA · doi:10.1001/jama.290.13.1757 · Cited by 340
Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System
Karsak, M., Gaffal, E., Date, R., Wang-Eckhardt, L., Rehnelt, J., Petrosino, S., Starowicz, K., Steuder, R., Schlicker, E., Cravatt, B., et al. (2007) · Science · doi:10.1126/science.1142265 · Cited by 338
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Zajicek, J. P. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.070136 · Cited by 335
Potency Trends of Δ9-THC and Other Cannabinoids in Confiscated Marijuana from 1980–1997
ElSohly, M., Ross, S., Mehmedic, Z., Arafat, R., Yi, B., & Banahan, B. (2000) · Journal of Forensic Sciences · doi:10.1520/jfs14636j · Cited by 308
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03674.x · Cited by 305 · cited 1×
“In a Phase II double-blind crossover study of intractable chronic pain (Notcutt et al 2004) in 24 subjects, visual analogue scales (VAS) were 5.9 for placebo, 5.45 for Nabidiolex, 4.63 for Tetranabinex and 4.4 for Sativex extracts (p 0.001).”
BackgroundInfluentialFlavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression.
Gerritsen, M. E., Carley, W. W., Ranges, G. E., Shen, C. P., Phan, S. A., Ligon, G. F., & Perry, C. A. (1995) · Europe PMC (PubMed Central) · Cited by 305
Nicholson, A. N., Turner, C., Stone, B. M., & Robson, P. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000125688.05091.8f · Cited by 291
Wade, D. T., Makela, P. M., House, H., Bateman, C., & Robson, P. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458505070618 · Cited by 285
Antihyperalgesic effects of spinal cannabinoids
Richardson, J. D., Aanonsen, L., & Hargreaves, K. M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01621-x · Cited by 275
CLINICAL STUDIES OF CANNABIS TOLERANCE AND DEPENDENCE*
Jones, R. T., Benowitz, N., & Bachman, J. (1976) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1976.tb49901.x · Cited by 270
Testing hypotheses about the relationship between cannabis use and psychosis
Degenhardt, L., Hall, W., & Lynskey, M. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00064-4 · Cited by 270
Howlett, A. C., Johnson, M. R., Melvin, L. S., & Milne, G. M. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13196-9 · Cited by 253
Abrams, D. I., Hilton, J. F., Leiser, R. J., Shade, S. B., Elbeik, T. A., Aweeka, F. T., Benowitz, N. L., Bredt, B. M., Kosel, B., Aberg, J. A., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-4-200308190-00008 · Cited by 238
Russo, E. B., Guy, G. W., & Robson, P. J. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790150 · Cited by 228
Self-citationWatson, S. J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.547 · Cited by 226
Why does the rapid delivery of drugs to the brain promote addiction?
Samaha, A.-N., & Robinson, T. E. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.007 · Cited by 204
Myrcene mimics the peripheral analgesic activity of lemongrass tea
Lorenzetti, B. B., Souza, G. E. P., Sarti, S. J., Santos Filho, D., & Ferreira, S. H. (1991) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(91)90187-i · Cited by 202
Hazekamp, A., Ruhaak, R., Zuurman, L., van Gerven, J., & Verpoorte, R. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20574 · Cited by 197
Linalool modifies the nicotinic receptor–ion channel kinetics at the mouse neuromuscular junction
Re, L., Barocci, S., Sonnino, S., Mencarelli, A., Vivani, C., Paolucci, G., Scarpantonio, A., Rinaldi, L., & Mosca, E. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0671 · Cited by 196
Russo, E. B. (2004) · PubMed · Cited by 186
Self-citationNadulski, T., Pragst, F., Weinberg, G., Roser, P., Schnelle, M., Fronk, E.-M., & Stadelmann, A. M. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000177223.19294.5c · Cited by 185
Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain
Buggy, D. J., Toogood, L., Maric, S., Sharpe, P., Lambert, D. G., & Rowbotham, D. J. (2003) · Pain · doi:10.1016/s0304-3959(03)00331-2 · Cited by 184
Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord
Hohmann, A. G., Briley, E. M., & Herkenham, M. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01321-3 · Cited by 183
Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia
Richardson, J. D., Aanonsen, L., & Hargreaves, K. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00451.1998 · Cited by 182
Walker, J. M., & Huang, S. M. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00252-8 · Cited by 176
Martin, W. J., Hohmann, A. G., & Walker, J. M. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-20-06601.1996 · Cited by 172
Holdcroft, A., Maze, M., Doré, C., Tebbs, S., & Thompson, S. (2006) · Anesthesiology · doi:10.1097/00000542-200605000-00021 · Cited by 166
Effects of nabilone, a synthetic cannabinoid, on postoperative pain
Beaulieu, P. (2006) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/bf03022793 · Cited by 161
Barnes, M. P. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.5.607 · Cited by 159
Akerman, S., Kaube, H., & Goadsby, P. J. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.059808 · Cited by 158
Smoked Marijuana as a Cause of Lung Injury
Tashkin, D. P. (2005) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2005.645 · Cited by 155
Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration
Cichewicz, D. L., & McCarthy, E. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045575 · Cited by 154
SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
Richardson, J. D., Aanonsen, L., & Hargreaves, K. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00952-1 · Cited by 149
Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure
Sarchielli, P., Pini, L. A., Coppola, F., Rossi, C., Baldi, A., Mancini, M. L., & Calabresi, P. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301246 · Cited by 149
Rahn, E. J., Makriyannis, A., & Hohmann, A. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707333 · Cited by 146
Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes.
Banerjee, S., Snyder, S. H., & Mechoulam, R. (1975) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30230-2 · Cited by 146
Nadulski, T., Sporkert, F., Schnelle, M., Stadelmann, A. M., Roser, P., Schefter, T., & Pragst, F. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.782 · Cited by 146
Gastric Cytoprotection of the Non-Steroidal Anti-Inflammatory Sesquiterpene, β-Caryophyllene
Tambe, Y., Tsujiuchi, H., Honda, G., Ikeshiro, Y., & Tanaka, S. (1996) · Planta Medica · doi:10.1055/s-2006-957942 · Cited by 145
Gibson, S. J. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.6.627 · Cited by 139
Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors
Akerman, S., Kaube, H., & Goadsby, P. J. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705896 · Cited by 135
The neurobiology of cannabinoid analgesia
Walker, J. M., Hohmann, A. G., Martin, W. J., Strangman, N. M., Huang, S. M., & Tsou, K. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00289-1 · Cited by 134
Neff, G. W., OʼBrien, C., Reddy, K. R., Bergasa, N. V., Regev, A., Molina, E. G., Amaro, R., Rodriguez, M. J., Chase, V., Jeffers, L. J., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05852.x · Cited by 134
Effect of myrcene on nociception in mice
Rao, V. S. N., Menezes, A. M. S., & Viana, G. S. B. (1990) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1990.tb07046.x · Cited by 133
Liu, J., Li, H., Burstein, S. H., Zurier, R. B., & Chen, J. D. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.983 · Cited by 129
Anti-inflammatory activity of oleoresin from Brazilian copaifera
Basile, A. C., Sertié, J. A. A., Freitas, P. C. D., & Zanini, A. C. (1988) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(88)90235-8 · Cited by 122
Berman, J. S., Lee, J., Cooper, M., Cannon, A., Sach, J., McKerral, S., Taggart, M., Symonds, C., Fishe, K., & Birch, R. (2003) · Anaesthesia · doi:10.1046/j.1365-2044.2003.03408_3.x · Cited by 122
Cichewicz, D. L., Martin, Z. L., Smith, F. L., & Welch, S. P. (1999) · PubMed · Cited by 121
Gieringer, D. H., Laurent, J. S., & Goodrich, S. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v04n01_02 · Cited by 121
Hohmann, A. G., Martin, W. J., Tsou, K., & Walker, J. M. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00196-d · Cited by 120
Cannabinoid (CB1) Receptor Activation Inhibits Trigeminovascular Neurons
Akerman, S., Holland, P. R., & Goadsby, P. J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106971 · Cited by 118
Russo, E. B. (1998) · Pain · doi:10.1016/s0304-3959(98)00033-5 · Cited by 117
Self-citationA review of the published literature into cannabis withdrawal symptoms in human users
Smith, N. T. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00026.x · Cited by 113
Cichewicz, D. L., & Welch, S. P. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046870 · Cited by 110
Cannflavin A and B, prenylated flavones fromCannabis sativa L.
Barrett, M. L., Scutt, A. M., & Evans, F. J. (1986) · Experientia · doi:10.1007/bf02118655 · Cited by 98
Experience with the Synthetic Cannabinoid Nabilone in Chronic Noncancer Pain
Berlach, D. M., Shir, Y., & Ware, M. A. (2006) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00085.x · Cited by 96
Manzanares, J., Corchero, J., Romero, J., Fernández‐Ruíz, J., Ramos, J. A., & Fuentes, J. A. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00371-9 · Cited by 93
Abuse Potential of Dronabinol (Marinol®)
Calhoun, S. R., Galloway, G. P., & Smith, D. E. (1998) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1998.10399689 · Cited by 93
Li, J., Daughters, R. S., Bullis, C., Bengiamin, R. N., Stucky, M. W., Brennan, J., & Simone, D. A. (1999) · Pain · doi:10.1016/s0304-3959(98)00263-2 · Cited by 90
Dyson, A., Peacock, M., Chen, A., Courade, J.-P., Yaqoob, M., Groarke, A., Brain, C., Loong, Y., & Fox, A. (2005) · Pain · doi:10.1016/j.pain.2005.03.037 · Cited by 85
Prostaglandins and cannabis—II inhibition of biosynthesis by the naturally occurring cannabinoids
Burstein, S., Levin, E., & Varanelli, C. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90158-5 · Cited by 84
Neurosurgery for Obsessive-Compulsive Disorder: Problems With Comorbidity
Albucher, R. C., Curtis, G. C., & Pitts, K. P. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.495a · Cited by 82
Strangman, N. M., & Walker, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.1.472 · Cited by 81
Treatment of Tourette’s Syndrome With Delta-9-Tetrahydrocannabinol
LLER-VAHL, K. R. M. ⁄., Schneider, U., KOLBE, H., & Emrich, H. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.495 · Cited by 77
Topical cannabinoid antinociception: synergy with spinal sites
Dogrul, A., Gül, H., Akar, A., Yıldız, O., Bilgin, F., & Güzeldemir, M. E. (2003) · Pain · doi:10.1016/s0304-3959(03)00068-x · Cited by 76
Cannabinoids: The separation of central from peripheral effects on a structural basis
Evans, F. (1991) · Planta Medica · doi:10.1055/s-2006-960231 · Cited by 76
Are oral cannabinoids safe and effective in refractory neuropathic pain?
Attal, N., Brasseur, L., Guirimand, D., Clermond‐Gnamien, S., Atlami, S., & Bouhassira, D. (2004) · European Journal of Pain · doi:10.1016/s1090-3801(03)00084-3 · Cited by 74
Combined cannabinoid therapy via an oromucosal spray
Pérez, J. (2006) · Drugs of today · doi:10.1358/dot.2006.42.8.1021517 · Cited by 73
Gómez, M. A., Sáenz, M. T., García, M. D., & Fernández, Á. (1999) · Zeitschrift für Naturforschung C · doi:10.1515/znc-1999-1113 · Cited by 73
Barnes, J. (1998) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.1998.tb00785.x · Cited by 71
Marihuana: The Forbidden Medicine
Strassman, R. J. (1998) · JAMA · doi:10.1001/jama.279.12.963-a · Cited by 71
Guy, G. W., & Robson, P. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n04_02 · Cited by 70
Neurobehavioral actions of cannabichromene and interactions with Δ9-tetrahydrocannabinol
Davis, W. M., & Hatoum, N. S. (1983) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(83)90004-6 · Cited by 67
Cannabinoid influence on cytokine profile in multiple sclerosis
Katona, S. J., Kaminski, E., Sanders, H., & Zajicek, J. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02803.x · Cited by 65
Schley, M. T., Legler, A., Skopp, G., Schmelz, M., Konrad, C. J., & Rukwied, R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112651 · Cited by 64
In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation
Challapalli, P. V. N., & Stinchcomb, A. L. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00262-4 · Cited by 60
Endocannabinoids and the gastrointestinal tract.
Massa, F., & Monory, K. (2006) · PubMed · Cited by 58
Ko, M., & Woods, J. H. (1999) · Psychopharmacology · doi:10.1007/s002130050955 · Cited by 58
Pharmacokinetics, metabolism and drug-abuse potential of nabilone
Lemberger, L., Rubin, A., Wolen, R. L., DESANTE, K. A., Rowe, H., Forney, R. B., & Pence, P. (1982) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(82)80031-5 · Cited by 58
Fimiani, C., Liberty, T., Aquirre, A. J., Amin, I., Ali, N., & Stefano, G. B. (1999) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(98)00068-9 · Cited by 52
Anti-inflammatory properties of cannabichromene
Wirth, P. W., Watson, E. S., ElSohly, M. A., Turner, C. E., & Murphy, J. C. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90631-1 · Cited by 51
Kogan, N. M. (2005) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955705774329555 · Cited by 48
King, L. A., Carpentier, C., & Griffiths, P. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.001137.x · Cited by 43
Comparative study of different essential oils of Bupleurum gibraltaricum Lamarck.
Gil, M. L., Jimenez, J., Ocete, M. A., Castañeda, A. Z., & Cabo, M. M. (1989) · PubMed · Cited by 42
Clinical Experience with Nabilone for Chronic Pain
Notcutt, W. G., Price, M., & Chapman, G. (1997) · Pharmacy and Pharmacology Communications · doi:10.1111/j.2042-7158.1997.tb00493.x · Cited by 40
Nicolodi, M., Volpe, A. R., & Sicuteri, F. (1998) · Cephalalgia · doi:10.1177/0333102498018s2111 · Cited by 39
Medical use of cannabis in the Netherlands
Gorter, R. W., Butorac, M., Cobian, E. P., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000152845.09088.28 · Cited by 36
Lynch, M. E., Young, J., & Clark, A. J. (2006) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.05.016 · Cited by 34 · cited 1×
“…neuropathic pain (Russo 2006b; Wade et al 2006), and government-approved research programs employing standardized herbal cannabis from Canada for chronic pain (Lynch et al 2006) and the Netherlands for general conditions (Janse et al 2004; Gorter et al 2005) over a period of several months or more.”
Background[The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain].
Clermont, S. G., Atlani, S., Attal, N., Mercier, F. L., Guirimand, F., & Brasseur, L. (2002) · PubMed · Cited by 28
Cannabidiol as a potential medicine
Pertwee, R. G. (2005) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7358-x_3 · Cited by 23
The Role of Cannabis and Cannabinoids in Pain Management
Ethan, R. (2005) · CRC Press eBooks · doi:10.1201/b14253-56 · Cited by 22
Decreased platelet aggregation following marihuana smoking in man.
Cf, S., Dj, B., Cg, G., et al. (1979) · PubMed · Cited by 20
Cannabidiol as an anxiolytic and antipsychotic
Zuardi, A. W., & Guimarães, F. S. (1998) · Cited by 20
Russo, E. B., Guy, G. W., & Robson, P. (2007) · ChemInform · doi:10.1002/chin.200747254 · Cited by 15
Self-citation
Cited by
Zou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,343
Aggarwal, S. K. (2013) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31824c5e4c · Cited by 62
de Vries, M., Van Rijckevorsel, D. C. M., Vissers, K. C. P., Wilder‐Smith, O. H. G., & Van Goor, H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12811 · Cited by 54
De Luca, C., Buratti, A., Krauke, Y., Stephan, S., Monks, K., Brighenti, V., Pellati, F., Cavazzini, A., Catani, M., & Felletti, S. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03862-y · Cited by 18
St-Amant, H., Ware, M. A., Julien, N., & Lacasse, A. (2015) · CMAJ Open · doi:10.9778/cmajo.20140095 · Cited by 10
Metadata
- Authors
- Russo, E.
- Venue
- Therapeutics and Clinical Risk Management
- Publisher
- Informa UK Limited
- Published
- 2008-02
- Volume
- Volume 4
- Issue
- 1
- Pages
- 245-259
- ISSN
- 1176-6336 (ISSN-L)
- 1178-203X
- OpenAlex
- W2160421955
- Cited by
- 294
- References
- 131
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.